Peptide Biomarkers for Chronic Pain Diagnosis

Neuropeptides and Chronic Pain

13 of 20

Studies examining somatic pain conditions found a positive correlation between CGRP levels and pain intensity, making it the most consistent peptide biomarker candidate.

Systematic review, Journal of Headache and Pain, 2017

Systematic review, Journal of Headache and Pain, 2017

View as image

Chronic pain has no blood test. Unlike diabetes (glucose), heart failure (BNP), or kidney disease (creatinine), there is no objective biomarker that confirms a chronic pain diagnosis or quantifies its severity. Clinicians rely on patient self-report, questionnaires, and clinical examination. This creates real problems: difficulty distinguishing pain subtypes, inability to predict treatment response, and persistent skepticism about conditions like fibromyalgia where pain exists without obvious tissue damage. Neuropeptides, the chemical messengers of pain signaling, are the leading candidates for filling this gap. Substance P, CGRP, beta-endorphin, neuropeptide Y, and nociceptin all change in measurable ways during chronic pain states. Whether those changes are consistent enough to form the basis of a diagnostic test is the question this article examines.

The Peptide Pain Panel: What Would a Blood Test Measure?

Five neuropeptide families dominate chronic pain biomarker research. Each operates through different mechanisms and is altered in different pain conditions.

Substance P

Substance P is an 11-amino-acid neuropeptide that transmits pain signals from peripheral nerves to the spinal cord and brain. It binds the neurokinin-1 (NK-1) receptor, amplifying pain perception and driving neurogenic inflammation. In chronic pain, substance P does not just report damage; it actively sensitizes the nervous system to perceive more pain from less stimulus.

The biomarker evidence: cerebrospinal fluid (CSF) substance P levels are consistently elevated in fibromyalgia patients compared to healthy controls. This finding has been replicated across multiple independent studies since the 1990s. Plasma (blood) substance P levels are less reliable, showing elevation in some chronic pain conditions but not others. The CSF-plasma discrepancy limits substance P's utility as a simple blood test.

Chen and colleagues confirmed in 2026 that the substance P/NK1 receptor system participates in central sensitization in chronic pain, using a spared nerve injury mouse model.^[5] Central sensitization is the mechanism by which the spinal cord amplifies pain signals, a hallmark of conditions like fibromyalgia, chronic widespread pain, and neuropathic pain. This confirms substance P's mechanistic role but does not resolve the measurement challenges.

CGRP (Calcitonin Gene-Related Peptide)

CGRP is the most validated peptide target in pain medicine. A 37-amino-acid neuropeptide released from trigeminal sensory neurons, CGRP dilates blood vessels, promotes neurogenic inflammation, and transmits pain signals in the trigeminovascular system. Its role in migraine is established beyond doubt: anti-CGRP therapies (erenumab, fremanezumab, galcanezumab, eptinezumab) are approved and effective.

As a biomarker, CGRP shows the strongest evidence. A systematic review published in the Journal of Headache and Pain found that 13 of 20 studies examining somatic pain conditions showed a positive correlation between CGRP levels and pain intensity. During migraine attacks, blood CGRP levels rise measurably, and interictal (between-attack) levels may be elevated in chronic migraineurs compared to episodic migraineurs or controls.

Hay and colleagues published a comprehensive pharmacological update on the calcitonin/CGRP peptide family in 2018, detailing the receptor subtypes, signaling pathways, and clinical implications of CGRP biology.^[3] Edvinsson reviewed the CGRP pathway as a viable therapeutic target in the same year, noting that the transition from biomarker observation to therapeutic intervention happened faster for CGRP than for any other pain peptide.^[2]

Graves and colleagues reported in 2026 that dual CGRP pathway antagonism (combining an anti-CGRP antibody with a gepant small molecule) shows potential for chronic migraine patients who partially respond to single-mechanism treatment.^[7] This pharmacological validation strengthens the case for CGRP as a meaningful biomarker: if blocking CGRP treats the pain, measuring CGRP should reflect the pain state.

Beta-Endorphin

Beta-endorphin is the body's most potent endogenous opioid peptide. Released by the pituitary gland and hypothalamus, it binds mu-opioid receptors to produce analgesia. In chronic pain, the endogenous opioid system is often dysregulated, and measuring beta-endorphin levels could theoretically indicate whether a patient's internal pain-suppression system is functioning normally.

Ho and colleagues demonstrated in 1989 that electroacupuncture increased opioid activity in the cerebrospinal fluid of chronic pain patients, with beta-endorphin elevated in 80% and dynorphin in 60% of treated patients.^[6] This showed that endogenous opioid levels respond to analgesic interventions and can be measured.

However, Kastrup and colleagues found in 1989 that while lidocaine treatment increased plasma beta-endorphin in diabetic neuropathy patients, pain relief did not correlate with beta-endorphin changes.^[4] This disconnection between measurable peptide changes and clinical outcomes is a recurring problem in pain biomarker research. For more on the endogenous opioid system, see endorphins, enkephalins, and dynorphins.

Neuropeptide Y

Neuropeptide Y (NPY) is a 36-amino-acid peptide that modulates pain processing, stress responses, and inflammation. In chronic pain conditions, NPY levels in blood and CSF show variable patterns. Some studies find decreased NPY in fibromyalgia (consistent with reduced stress resilience), while others find increased NPY in complex regional pain syndrome (CRPS) during acute phases. The direction of change appears to depend on the specific pain condition, the chronicity, and the body compartment measured.

Nociceptin/Orphanin FQ

Nociceptin (also called orphanin FQ) is structurally similar to dynorphin but acts on the NOP receptor rather than classical opioid receptors. Its role in pain is paradoxical: it can be both pro-nociceptive and anti-nociceptive depending on the dose, route, and pain model. This pharmacological complexity makes it a poor standalone biomarker candidate, though it may contribute to multi-peptide diagnostic panels.

Why No Peptide Blood Test Exists Yet

Despite decades of research, no peptide-based blood test for chronic pain has been validated for clinical use. Several obstacles explain this gap.

Compartmentalization. Pain signaling occurs in the spinal cord, brainstem, and peripheral nerves. Peptide levels in these compartments do not reliably mirror blood levels. Substance P is elevated in CSF but inconsistently in plasma. CGRP is measurable in blood during migraine attacks but not reliably in other pain states.

Temporal variability. Neuropeptide levels fluctuate with circadian rhythms, stress, food intake, physical activity, and medication use. A single blood draw captures one moment, not the dynamic peptide landscape that characterizes chronic pain.

Condition specificity. CGRP is informative for migraine. Substance P for fibromyalgia. Beta-endorphin for opioid system dysfunction. No single peptide works across all chronic pain conditions, and multi-peptide panels have not been standardized.

Measurement sensitivity. Many neuropeptides circulate at picomolar concentrations. Accurate measurement requires specialized immunoassays or mass spectrometry that are not available in standard clinical laboratories. Sample handling matters: neuropeptides degrade rapidly without protease inhibitors, and improper collection can produce false results.

Abbas and colleagues are addressing some of these challenges in a 2026 study assessing pain-related biomarkers specifically in migraine and tension headache patients, attempting to identify which peptide measurements have sufficient sensitivity and specificity for clinical differentiation.^[1]

The Multi-Peptide Panel Approach

The most promising direction is not a single-peptide test but a panel measuring multiple neuropeptides simultaneously. A chronic pain biomarker panel might include:

• CGRP (elevated = migraine-type neurovascular pain)
• Substance P (elevated = central sensitization, fibromyalgia-type pain)
• Beta-endorphin (decreased = inadequate endogenous analgesia)
• NPY (decreased = reduced stress resilience, pain vulnerability)
• Inflammatory cytokines (IL-6, TNF-alpha, as comparators for inflammatory vs. neuropathic pain)

This pattern-based approach could theoretically differentiate migraine from tension headache, fibromyalgia from inflammatory arthritis, or neuropathic pain from nociceptive pain. The neuropeptide dysregulation patterns in specific pain conditions support this concept.

No multi-peptide panel for chronic pain has been validated in prospective clinical trials. The concept exists in the research literature but not in clinical practice.

What CGRP Therapeutics Teach About Biomarkers

The CGRP story provides the clearest example of the biomarker-to-therapy pipeline in pain medicine. The sequence:

1. Observation: CGRP levels rise during migraine attacks (biomarker discovery, 1980s-1990s)
2. Validation: CGRP infusion triggers migraine-like attacks in susceptible individuals (mechanistic confirmation)
3. Therapeutic proof: CGRP receptor antagonists (gepants) and anti-CGRP antibodies prevent and treat migraine (clinical validation)
4. Biomarker refinement: CGRP levels may predict treatment response (personalized medicine application, under investigation)

Hallberg and colleagues explored a parallel path for substance P, finding that the metabolite SP(1-7) has antinociceptive (pain-reducing) properties, opposite to the full-length peptide.^[4] This suggests that measuring not just neuropeptide levels but their metabolic fragments could provide additional diagnostic information. A patient with high substance P and low SP(1-7) might have a different pain phenotype than one with high levels of both.

Condition-Specific Peptide Signatures

Different chronic pain conditions appear to produce different neuropeptide patterns, which supports the multi-panel biomarker concept.

Migraine: Elevated CGRP during attacks, potentially elevated interictal CGRP in chronic migraine. Substance P may be co-elevated. Beta-endorphin shows inconsistent patterns.

Fibromyalgia: Elevated CSF substance P (2-3 times normal in some studies), decreased NPY, variable beta-endorphin. This pattern is consistent with central sensitization combined with reduced stress-buffering capacity.

Complex regional pain syndrome (CRPS): CGRP, substance P, NPY, and bradykinin are elevated in blood near the affected limb during acute phases. Neuropeptide levels normalize as CRPS transitions from acute to chronic stages, suggesting the biomarker window may be time-limited.

Neuropathic pain: Altered substance P/NK1R signaling at the spinal cord level. Dynorphin may be elevated, which paradoxically contributes to pain maintenance rather than suppression in chronic neuropathic states. Beta-endorphin responses to analgesic stimulation may be blunted.

Inflammatory pain (rheumatoid arthritis, IBD): Substance P and CGRP are elevated in affected tissues and may be reflected in plasma. These changes overlap with inflammatory cytokine elevations, making it difficult to determine whether peptide measurement adds diagnostic value beyond existing inflammatory markers.

The specificity of these patterns has not been tested in a diagnostic validation study. Most research examines one condition at a time, comparing patients to healthy controls. The clinically relevant comparison, distinguishing fibromyalgia from neuropathic pain, or migraine from tension headache, requires head-to-head studies with standardized peptide measurement protocols. Abbas and colleagues are working toward this with their 2026 assessment of pain-related biomarkers in migraine versus tension headache patients.^[1]

The Bottom Line

Neuropeptides are measurably altered in chronic pain conditions, but no peptide blood test has reached clinical use for pain diagnosis. CGRP has the strongest evidence as a biomarker, particularly for migraine, supported by therapeutic validation through anti-CGRP drugs. Substance P levels in cerebrospinal fluid correlate with fibromyalgia but are unreliable in blood. Beta-endorphin, NPY, and nociceptin show condition-specific changes that are not yet consistent enough for diagnostic application. The most promising research direction is multi-peptide panels that characterize pain subtypes through pattern recognition rather than single-analyte thresholds.

Frequently Asked Questions

Is there a blood test for chronic pain?

No validated blood test for chronic pain exists as of 2026. Neuropeptides like CGRP, substance P, and beta-endorphin change measurably in chronic pain conditions, but no single peptide measurement has sufficient sensitivity and specificity for clinical diagnosis. Research is ongoing into multi-peptide panels that might differentiate pain subtypes, but these have not been validated in prospective clinical trials.

What does substance P have to do with pain?

Substance P is an 11-amino-acid neuropeptide that transmits pain signals from peripheral nerves to the spinal cord and amplifies pain perception through the NK-1 receptor. In fibromyalgia, cerebrospinal fluid substance P levels are consistently elevated compared to healthy controls. Chen et al. confirmed in 2026 that the substance P/NK1R system participates in central sensitization, the spinal cord amplification mechanism that drives chronic pain.

Can CGRP levels predict migraines?

CGRP levels rise measurably during migraine attacks, and interictal (between-attack) levels may be elevated in chronic compared to episodic migraineurs. A systematic review found CGRP correlated with pain intensity in 13 of 20 somatic pain studies. Whether CGRP levels can predict individual migraine attacks before they occur is not established, but higher baseline CGRP may identify patients more likely to respond to anti-CGRP therapies.

What are endogenous opioid peptides?

Endogenous opioid peptides (beta-endorphin, enkephalins, dynorphins) are the body's natural painkillers. They bind mu, delta, and kappa opioid receptors to suppress pain signaling. In chronic pain, endogenous opioid system dysfunction may contribute to pain persistence. Ho et al. showed that electroacupuncture increased CSF beta-endorphin in 80% of chronic pain patients, demonstrating these peptides are measurable and respond to analgesic interventions.

Why is fibromyalgia so hard to diagnose?

Fibromyalgia produces widespread pain without detectable tissue damage on standard imaging or blood tests. Diagnosis relies on clinical criteria (widespread pain, fatigue, cognitive symptoms) and exclusion of other conditions. Elevated cerebrospinal fluid substance P is one of the most consistent biological findings, but CSF collection (lumbar puncture) is too invasive for routine diagnosis. A validated blood biomarker panel could transform fibromyalgia diagnosis, but none exists yet.

What peptides are involved in pain signaling?

The main peptides in pain signaling include substance P (amplifies pain transmission), CGRP (neurovascular pain and migraine), beta-endorphin (endogenous pain suppression), enkephalins and dynorphins (opioid-mediated analgesia), neuropeptide Y (pain modulation and stress resilience), and nociceptin/orphanin FQ (complex bidirectional pain modulation). Each operates through distinct receptors and pathways, which is why chronic pain is not a single disease but a family of conditions with different peptide signatures.